Clinical trial Recruiting at 1 site Interventional Ages 18 to 40

Using PRP injections to treat knee osteoarthritis in young athletes

Official title: Homologus PRP in the Infiltrative Treatment of Knee Osteoarthritis in Young Athletic Patients

Run by Istituto Ortopedico Rizzoli · NCT06483269 · Data updated 2026-11-12

This study is testing if PRP injections can help young athletes with knee osteoarthritis feel better and improve their joint health.

More Knee Osteoarthritis trials

Quick facts

Study typeInterventional
Ages18 Years to 40 Years
SexAll
Enrollment30 (estimated)
SponsorIstituto Ortopedico Rizzoli
Academic / other
Locations1 site (Bologna)
StatusRecruiting
StartedOctober 10, 2023
Main results expectedSeptember 2026
Study endsSeptember 2026
Registry record updatedJuly 4, 2025
Trial IDNCT06483269 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are young adults aged 18-40 with unilateral knee osteoarthritis and moderate pain levels.

Probably not a fit

Patients with recent knee surgeries, other significant health issues, or those unable to consent may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of homologous platelet-rich plasma (PRP) injections for treating knee osteoarthritis in young athletic patients aged 18-40. The trial involves a three-phase approach, including patient enrollment, the infiltrative procedure, and follow-up assessments at 1, 3, 6, and 12 months post-treatment. Patients will undergo clinical evaluations and complete questionnaires to assess pain levels and joint function, while any adverse events will also be monitored. The goal is to determine the impact of PRP on symptoms and joint health in this specific patient population.

Why it matters

Potential benefit: If successful, this treatment could provide a less invasive option for managing knee osteoarthritis symptoms in young athletes, potentially improving their quality of life and athletic performance.

How similar studies have gone: Previous studies have shown promising results with PRP injections for knee osteoarthritis, suggesting potential effectiveness in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients, both sexes, with symptomatic knee osteoarthritis with:
* Age: 18-40 years;
* Unilateral involvement;
* Signs and symptoms of knee osteoarthritis;
* Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);
* Ability and consent of patients to actively participate in clinical follow-up;
* Signature of informed consent;
* Pain ≥ 4 on VAS s

Exclusion Criteria:

* Patients unable to express consent;
* Patients undergoing intra-articular infiltration of other substance in the previous 6 months;
* Patients undergoing knee surgery in the previous 12 months;
* Patients with malignant neoplasms;
* Patients with rheumatic diseases;
* Patients with uncontrolled metabolic diseases;
* Patients with hematological diseases (coagulopathies);
* Patients abusing alcoholic beverages, drugs or medications;
* Knee trauma treated in the previous 6 months.
* Other conditions that may interfere with the evaluation of OA treatment.

Where it's running

  • IRCCS - Istituto ortopedico Rizzoli
    Bologna, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.